Table 1 Demographic and clinical characteristics of the population
From: Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
Characteristic | Azvudine (N = 88) | Paxlovid (N = 83) | Total (N = 171) |
|---|---|---|---|
Mean age on admission (range) — yr | 70.3 (25–90) | 70.1 (36–89) | 70.7 (25–90) |
Sex—no. (%) | |||
Male | 55 (62.5%) | 53 (63.9%) | 108 (63.2%) |
Female | 33 (37.5%) | 30 (36.1%) | 63 (36.8%) |
Vaccination status—no. (%) | |||
Unvaccinated | 42 (47.7%) | 27 (32.5%) | 69 (40.4%) |
Vaccinated | 46 (52.3%) | 56 (67.5%) | 102 (59.6%) |
BMI—no. (%) | |||
BMI ≥ 25 | 50 (56.8%) | 49 (59.0%) | 99 (57.9%) |
BMI < 25 | 38 (43.2%) | 34 (41.0%) | 72 (42.1%) |
Risk factors for severe illness from Covid-19 — no. (%) | |||
Age ≥ 60 yr | 76 (86.4%) | 68 (81.9%) | 144 (84.2%) |
Hypertension | 40 (45.5%) | 31 (37.3%) | 71 (41.5%) |
Diabetes | 26 (29.5%) | 9 (10.8%) | 35 (20.5%) |
Coronary Disease | 22 (25.0%) | 21 (25.3%) | 43 (25.1%) |
Stroke | 10 (11.4%) | 8 (9.6%) | 18 (10.5%) |
COPD | 7 (8.0%) | 16 (19.3%) | 23 (13.5%) |
Malignant Tumor | 10 (11.4%) | 8 (9.6%) | 18 (10.5%) |